Table 42 (abstract P120). See text for description
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Number of patients | Whole group | Diffuse subtype | Limited subtype | 0.945 |
|---|---|---|---|---|
Sex female /male | 80 | 57 (71%) | 23 (29%) | |
Medication | 66/14 = > 4.7:1 | 47/10 = > 4.7:1 | 20/4 = > 5:1 | |
62/71 (87%) | 44/50 (88%) | 18/21 (86%) | ||
Corticosteroids | 36/62 (58%) | 27/44 (61%) | 9/18 (50%) | 0.667 |
Cyclophosphamide | 5/62 (8%) | 5/44 (11%) | 0/18 (0%) | 0.159 |
Chloroquine/Hydroxy-chlorqquine | 10/62 (16%) | 6/44 (14%) | 4/18 (22%) | 0.485 |
Methotrexate | 35/62 (56%) | 24/44 (54%) | 11/18 (61%) | 0.804 |
Mycophenolate | 11/62 (18%) | 8/44 (18%) | 3/18 (17%) | 0.905 |
Azathioprin | 1/62 (2%) | 1/44 (2%) | 0/18 (0%) | 0.524 |
Tocolizumab | 1/62 (2%) | 0/44 (0%) | 1/18 (6%) | 0.125 |
Rituximab | 2/62 (3%) | 1/4 (2%) | 1/18 (6%) | 0.523 |
Bosentan | 11/62 (18%) | 10/44 (23%) | 1/18 (6%) | 0.165 |
PDE5 inhibitors | 4/62 (6%) | 3/4 (7%) | 1/18 (6%) | 0.863 |
Prostanoids | 1/62 (2%) | 0/44 (0%) | 1/18 (6%) | 0.125 |